Atlas Trials

Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

Clinical trial NCT03946449 · COMPLETED

Trial details

NCT number
NCT03946449
Sponsor
Arrowhead Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Alpha 1-Antitrypsin Deficiency
Start date
2019-10-31
Primary completion
2022-04-28
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.